We are international
Donate
TEXT SIZE   


Pierre S. Sayad Joins IMF as Senior Vice President, Global Medical Affairs and Strategic Partnerships
06.01.16

Pierre S. Sayad has joined the IMF as Senior Vice President, Global Medical and Scientific Affairs. Pierre completed his graduate work in Molecular Physiology at Loma Linda University, School of Medicine. In 2003, he began his pharmaceutical career at Eli Lilly and Company, and held leadership roles across Commercial and Medical Affairs teams. During his ten-year tenure at Lilly, Pierre helped launch four blockbuster neuroscience medicines for various mental illnesses.  

After Lilly, Pierre joined the management-consulting firm, Campbell Alliance. As a senior consultant managing projects in the Medical Affairs and Commercial practice areas, Pierre worked with clients at more than 25 pharmaceutical and biotech companies, including Pfizer, Genentech, Novartis, and GSK. In 2012, he joined Onyx Pharmaceuticals as head of Global Strategy and Operations for the Medical and Scientific Affairs Organization. He ultimately formalized and launched Onyx’s Global Strategic Partnerships program, and was heavily involved in Onyx’s transition to Amgen.

Given his role at Onyx (a subsidiary of Amgen), Pierre has been very familiar with the IMF’s Black Swan Research Initiative® and the organization’s other innovative platforms aimed at curing Myeloma.  He currently works directly with the IMF President and the Chairman of the Board, and is committed to advancing myeloma treatment paradigms, ultimately improving the lives of patients.


 related videos
 related articles
ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
"Understanding Health Disparities in Cancer: The Case of Multiple Myeloma"
Understanding Freelite and Hevylite Tests
ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
Best of ASH 2013: What Patients Need to Know
BLACK SWAN RESEARCH INITIATIVE™ DONOR LEVELS
BLACK SWAN RESEARCH INITIATIVE™ MEDIA CONTACT
BRAZIL WORKSHOP
California Support Group Leader’s Testimony Makes Huge Difference
Cancer Awareness Bracelets
Dr. Brian Durie, Chairman of the International Myeloma Foundation, Honored by Mayo Clinic With Distinguished Alumni Award
Global Myeloma Action Network (GMAN)
IMF Nurse Leadership Board (NLB) Survivorship Care Plan for Mutliple Myeloma published in the Clinical Journal of Oncology Nursing.
IMF's 8th Annual Comedy Celebration: Big Laughs, Big Success
International Myeloma Foundation (IMF) Funds First Large-Scale Screening to Identify and Treat Precursor of Blood Cancer Before Disease Develops
International Myeloma Foundation (IMF)
Flow Workshop Presentations
July 18-19, 2014
International Myeloma Foundation Mission Statement
Mensajero del Mieloma - Otoño 2012 - #903
Michael and Robin Tuohy of Connecticut Help to Pass State Oral Parity Bill
Myeloma Minute
March 26, 2015
Pomalidomide News: Promising Results Increase Chances of Early Drug Approval
Raise Your Voice Web Series
Sign up TODAY for Advocacy Training Two-Part Online Series!
Supreme Court Upholds Affordable Care Act
The International Myeloma Foundation Applauds Wisconsin Gov. Scott Walker for Signing SB 300 (The Cancer Treatment Fairness Act) into Law
The Military Veterans Perspective on Living with Multiple Myeloma
What does ‘dysplasia’ mean within the bone marrow report?